Sponsor

Affiliated Cancer Hospital & Institute of Guangzhou Medical University

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Affiliated Cancer Hospital & Institute of Guangzhou Medical University appears in 11 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials11
Recruiting shown0
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

11 shown
Analgesic Efficacy of an Opioid-free Postoperative Pain Management Strategy Versus a Conventional Opioid-based Strategy Following Video-assisted Thoracoscopic LobectomyNCT06570538 · lead sponsor · 2024-09-01
UNKNOWN
Prospective Study of Serum Marker LncRNA RP5-977B1 in Pulmonary NodulesNCT06531850 · lead sponsor · 2024-01-01
UNKNOWN
Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With OligometastasesNCT05484583 · lead sponsor · 2022-08-01
NOT_YET_RECRUITING
Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLCNCT05448781 · lead sponsor · 2022-07-20
UNKNOWN
Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung CancerNCT04922658 · lead sponsor · 2020-06-03
ACTIVE_NOT_RECRUITING
Rh-Endostatin (Endostar®) Continuous Intravenous InfusionNCT03706703 · lead sponsor · 2018-10-01
UNKNOWN
Clinical Pharmacokinetics of TKIs in Chinese Patients of Hepatitis B (HBV)NCT03680183 · lead sponsor · 2018-05-22
UNKNOWN
Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLCNCT07703228 · collaborator · 2025-08-13
ACTIVE_NOT_RECRUITING
A Prospective, Non-interventional Cohort Study of Subsolid Pulmonary NodulesNCT06458673 · collaborator · 2024-12-01
NOT_YET_RECRUITING
D-CIK Combined With Chemotherapy for Non-Small Cell Lung Cancer(NSCLC)NCT02651441 · collaborator · 2016-02-01
UNKNOWN
A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.NCT02521441 · collaborator · 2014-07-03
COMPLETED

Drugs studied in this sponsor's trials

8 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Affiliated Cancer Hospital & Institute of Guangzhou Medical University as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
carboplatin1
cisplatin1
docetaxel1
durvalumab1
gemcitabine1
pemetrexed1
ropivacaine1
sufentanil1

Sponsor roles

lead sponsor7
collaborator4
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.